3 assets in Congenital Fibrosarcoma
Therapeutic assets addressing Congenital Fibrosarcoma, rated under Floatz methodology v0.2 and sorted by current rating.
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
Selpercatinib Congenital Fibrosarcoma | Eli Lilly and Company | P1/2 | CCC (48) |